We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 05, 2020

PFS and OS in Patients With Advanced HER2+ Breast Cancer Treated With T-DM1 After Previous Treatment With Pertuzumab

Cancers

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancers
Progression-Free Survival and Overall Survival in Patients With Advanced HER2-Positive Breast Cancer Treated With Trastuzumab Emtansine (T-DM1) After Previous Treatment With Pertuzumab
Cancers (Basel) 2020 Oct 17;[EPub Ahead of Print], LL Michel, AD Hartkopf, PA Fasching, HC Kolberg, P Hadji, H Tesch, L Häberle, J Ettl, D Lüftner, M Wallwiener, V Müller, MW Beckmann, E Belleville, B Volz, H Huebner, P Wimberger, C Hielscher, C Mundhenke, C Kurbacher, R Wuerstlein, M Untch, F Overkamp, J Huober, W Janni, FA Taran, MP Lux, D Wallwiener, SY Brucker, A Schneeweiss, TN Fehm

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading